Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13
Rhea-AI Summary
Vaxart (NASDAQ: VXRT) has scheduled its first quarter 2025 business update and financial results conference call for May 13, 2025, at 4:30 p.m. ET, following the market close. The company's senior management team will host the conference call, which will be accessible via webcast and telephone. Investors can participate using domestic line (877) 407-0832 or international line (201) 689-8433 with Conference ID 13753354. Investors may submit questions in advance to ir@vaxart.com by May 12, 2025. A replay of the webcast will be available on Vaxart's website after the event.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the trading session that priced this news, VXRT gained 4.92%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Tuesday, May 13, 2025 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13753354
Investors may submit written questions in advance of the conference call to ir@vaxart.com by May 12, 2025.
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
